Jing Rong
戎璟
Jing Rong is a managing director (董事总经理) at BlueRun Ventures (蓝驰创投), where she has spoken publicly on the firm's investment strategy and portfolio since at least 2022 . Her coverage at BlueRun has centered on biotechnology—she has presented at multiple BlueRun biotech forums and salons on topics including peptide drugs and the path from lab to commercialization for pharmaceutical startups . She has also represented the firm at annual partner meetings, where in 2023 she discussed BlueRun's biotech track alongside robotics and digital tech , and in 2025 she was grouped with the firm's bets on embodied intelligence, biotech, and advanced computing . Beyond sector talks, she has moderated roundtables on industrial intelligence and helped convene BlueRun portfolio companies with listed-firm representatives at the firm's "Blueprint" ecosystem events in Shenzhen .
Related coverage: BlueRun Ventures' 2026 recruitment push for its AdventureX program ; portfolio updates including NanoCore Chips' Series B and Zero Gravity Aircraft's Series A ; and AgiBot's 2024 product launch .
AI-generated — may contain errors, please verify.
Coverage
Dawn Breaks, Toward the Light | BlueRun Ventures 2025 Annual Fund Partners Meeting
Welcoming the Dawn of Technology
Beyond the Quadrant: Forging an Undefined Path | BlueRun Ventures 2024 Annual Fund Partners Meeting
Breaking Through a Mental Block
The Trillion-Yuan Blueprint for Peptide Drugs: From Diabetes Medication to Weight-Loss Wonder | BlueRun Ventures Biotech Forum Recap
From Pharmaceuticals to Consumer Goods: A Wave of Value Creation
BlueRun Ventures Launches "Blueprint" Industrial Ecosystem Platform: Entering Shenzhen to Co-Create a Vision for Industrial Intelligence
BlueRun Ventures is building a platform to connect technology innovation companies with industrial ecosystems.
A Pill's Journey from Lab to Industry | BlueRun Ventures Biotech Salon Series
The investment logic in biotech has quietly shifted.
Facing Towering Waves and Endless Voyages, We Climb Without Cease | 2023 Annual Fund Partners Meeting
Riding Out Cycles, Embracing Change
BlueRun Ventures Leads Series B Financing Round of Over 100 Million RMB for QLT Biotechnology | BlueRun Ventures Portfolio
It is poised to become one of the key players in the metabolic disease space, both domestically and globally.
BlueRun Ventures Leads Angel Round of Several Tens of Millions of Yuan for Brain-Computer Intelligence Company Weiling Medical | BlueRun Ventures
Mastery of full-chain, independently developed, internationally leading minimally invasive implantable brain-computer interface technology
The Era of Value Rediscovery: Finding "The Next Big Thing" in Biotech | A BlueRun Ventures Perspective
Technology-driven, seeking next-generation biotech companies aligned with industry logic
